Anti-Amyloid Monoclonal Antibodies Market Size
Anti-Amyloid Monoclonal Antibodies Market reached US$ 0.64 billion in 2025 and is expected to reach US$ 6.71 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2026-2033.
Anti-amyloid monoclonal antibodies are the disease-modifying therapies for Alzheimer's disease. These agents slow down the progression of the disease and prevent further cognitive impairment. Currently, two anti-amyloid monoclonal antibodies are approved, and they are lecanemab and donanemab. These agents are considered disease-modifying therapies, as they produce a marked reduction in amyloid plaques when observed on amyloid positron emission tomography (PET). A 30% reduction in the decline of cognitive impairment is considered statistically significant, and these agents in their clinical testing phases, especially donanemab, have reduced the cognitive decline by 32%, and lecanemab reduced the cognitive decline by 27%. The manufacturer of aducanumab has announced its discontinuation in January 2024, but the drug is made available for people who are receiving it in clinical trials.
The market for these monoclonal antibodies is experiencing significant growth due to rising market access across various geographies, and increasing awareness of early Alzheimer's diagnosis, combined with advancements in diagnostic technologies such as amyloid PET imaging and cerebrospinal fluid biomarkers. As healthcare systems begin to integrate these innovations, the demand for disease-modifying treatments like lecanemab and donanemab is growing.
Executive Summary
Anti-Amyloid Monoclonal Antibodies Market Scope
| Metrics | Details | |
| CAGR | 21.6% | |
| Market Size Available for Years | 2025-2033 | |
| Estimation Forecast Period | 2026-2033 | |
| Revenue Units | Value (US$ Mn) | |
| Segments Covered | Product | Donanemab and Lecanemab |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and the Middle East & Africa | |
Explore the Future of the Anti-Amyloid Monoclonal Antibodies Market
Get a comprehensive sample report covering Anti-Amyloid Monoclonal Antibodies Market trends, therapeutic advancements, competitive landscape, application insights, and growth opportunities. Request your sample today to understand the factors shaping the next generation of Alzheimer’s disease treatment and innovative antibody-based therapies.Request Sample Report Today!
Anti-Amyloid Monoclonal Antibodies Market Dynamics Drivers & Restraints
The rising prevalence of alzheimer’s disease is driving the market growth
At present 8 drugs are approved and available in the market for Alzheimer's disease, of which 3 are the disease-modifying drugs that can change the underlying pathology. These disease-modifying drugs play a crucial role in reducing the disease progression and improvement of cognitive function in Alzheimer's patients. As the number of patients increases, the demand for these advanced therapies is expected to rise.
For instance, according to a recent epidemiology study published in the Lancet Public Health journal, nearly 152.8 million dementia cases are expected to be reported by 2050, from 57.4 million in 2019. This increase is attributable to population growth and population aging. According to the Alzheimer's Association, 60% to 80% of dementia cases are due to Alzheimer's disease.
High cost of monoclonal antibodies may restrain the market growth
The high cost of anti-amyloid monoclonal antibodies may restrain the market growth in the forecasted period. Since the current available anti-amyloid monoclonal antibodies are newer agents and are sold under brand names, these drugs are more expensive This high cost may result in lower adoption among the patient population living in low and middle-income countries.
For instance, Kisunla (donanemab) by Eli Lilly and LEQEMBI by Eisai are the two currently available anti-amyloid monoclonal antibodies. The per-patient treatment cost in the U.S. is as follows.
Name of the Drug | Manufacturer | Listed Price in U.S. | Annual Cost of Treatment |
Kisunla (donanemab) | Eli Lilly and Company | US$ 695.65 per Vial | US$ 32,000.00 |
LEQEMBI (lecanemab) | Eisai Inc. | US$ 637.02 (500mg Vial) | US$ 26,500.00 |
Anti-Amyloid Monoclonal Antibodies Market Segment Analysis
The global anti-amyloid monoclonal antibodies market is segmented based on product and region.
Lecanemab in the product segment accounted for 54.9% of the market share in 2024 in the global anti-amyloid monoclonal antibodies market.
Lecanemab, sold under the brand name Leqembi co-developed by Eisai Inc. and Biogen. It is the first anti-amyloid monoclonal antibody approved in different countries across the world. Leqembi is a prescription medicine for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease. Leqembi is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, which is the main pathological feature of Alzheimer’s disease.
Post its approval from the U.S. Food and Drug Administration (FDA), Leqembi has expanded its presence across the globe. The drug is now available in all regions. According to the latest reports of Eisai Inc., Leqembi has a revenue growth of 108.1% from the previous financial year. The company also aims to generate a sales value of approximately US$ 300 million in the next financial year (April 1, 2024, to March 31, 2025).
Anti-Amyloid Monoclonal Antibodies Market Geographical Analysis
North America dominated the anti-amyloid monoclonal antibodies market with the highest share of 65.3% in 2024
North America is expected to hold a significant market share and grow with the highest CAGR in the forecast period due to various factors, including higher demand for novel therapies, major revenue generated by market players, and higher prevalence of Alzheimer’s disease.
For instance, according to the annual report by the Alzheimer’s Association, nearly 6.9 million Americans aged 65 and older are living with Alzheimer’s dementia in 2024, and the number of patients is expected to reach 8.5 million by 2030, 11.2 million by 2040, and 12.7 million by 2050.
This rising prevalence of Alzheimer’s disease is attributable to the aging population. The population above 65 years of age is expected to reach 82 million by 2050, from 58 million in 2022.
In addition to higher prevalence, North America is the hotspot for any novel drug launch. Due to favorable yet stringent regulatory policies, higher expenditure on research and development activities, higher expenditure on healthcare, higher per-capita income, and spending on healthcare, manufacturers intend to launch their products in the U.S. market first. Their products are sold at higher prices in the North America market as compared to other nations. Due to this, manufacturers generate a majority of their revenue from the region.
For instance, the latest anti-amyloid monoclonal antibody Kisunla (donanemab), developed by Eli Lilly and Company, was first approved by the U.S. Food and Drug Administration (FDA) in July 2024. Post the FDA approval in the U.S., the product received approval in the European Market in October 2024. This reflects the early access of the drug to U.S. patients.
All these factors contribute to the dominance of the North America region in the anti-amyloid monoclonal antibodies market.
Anti-Amyloid Monoclonal Antibodies Market Major Players
The major players in the anti-amyloid monoclonal antibodies market are Eli Lilly and Company., Eisai Co., Ltd. and Biogen Inc., among others.
Anti-Amyloid Monoclonal Antibodies Market Recent Development
- August 2026 – Eisai and Biogen expand U.S. availability of subcutaneous lecanemab
Eisai and Biogen made LEQEMBI IQLIK (lecanemab-irmb) available in the U.S. as a once-weekly subcutaneous initiation treatment for early Alzheimer’s disease. The autoinjector-based option enables at-home administration and provides an alternative to intravenous infusion, supporting greater treatment convenience and potentially broader adoption of anti-amyloid therapies. - July 2026 – FDA approves subcutaneous LEQEMBI IQLIK for early Alzheimer’s disease
The U.S. FDA approved LEQEMBI IQLIK as an initiation dose for early Alzheimer’s disease, allowing patients to receive lecanemab through a once-weekly subcutaneous injection. The approval expands the administration options for an anti-amyloid monoclonal antibody and strengthens the commercial outlook for more convenient treatment delivery models. - July 2026 – Real-world evidence strengthens lecanemab treatment outlook
Eisai and Biogen presented results from the LEADER real-world study at AAIC 2026, showing that approximately 83% of enrolled early Alzheimer’s patients remained stable or improved over an average of 17 months of LEQEMBI treatment. The findings provide additional real-world evidence supporting continued treatment and long-term use of lecanemab. - July 2026 – Eli Lilly expands long-term evidence for donanemab
Eli Lilly presented new analyses of KISUNLA (donanemab-azbt) at AAIC 2026, including long-term extension data examining its benefit-risk profile. The company also highlighted research covering treatment outcomes, real-world prescribing, patient-centered outcomes and amyloid-targeting therapy, reinforcing donanemab's position in the anti-amyloid treatment landscape. - June 2026 – Eisai advances global development of lecanemab administration options
Eisai highlighted continued regulatory and development activity surrounding subcutaneous lecanemab, including applications and regulatory progress in international markets. The company also continued the AHEAD 3-45 Phase 3 study evaluating lecanemab in individuals with preclinical Alzheimer’s disease, supporting the industry's shift toward earlier intervention before significant cognitive symptoms emerge. - June 2026 – Biogen expands clinical evidence for lecanemab at AAIC 2026
Biogen announced new data presentations covering subcutaneous administration, real-world use, maintenance dosing and patient experience with LEQEMBI. The company also highlighted continued development across amyloid and tau targets, reflecting growing interest in complementary approaches to Alzheimer's disease treatment. - May 2026 – FDA review advances for once-weekly subcutaneous lecanemab
The FDA extended its review of the supplemental application for once-weekly subcutaneous LEQEMBI IQLIK to allow additional time to evaluate requested information. The regulatory process underscored the industry's continued focus on moving anti-amyloid monoclonal antibody therapy from infusion-based delivery toward more convenient subcutaneous administration. - 2026 – Donanemab clinical development expands toward preclinical Alzheimer’s disease
Eli Lilly continued advancing donanemab studies beyond symptomatic early Alzheimer’s disease, including TRAILBLAZER-ALZ 3, a Phase 3 study evaluating donanemab in preclinical Alzheimer’s disease. This expansion reflects the broader market trend toward testing anti-amyloid monoclonal antibodies earlier in the disease continuum. - 2026 – Anti-amyloid pipeline increasingly incorporates combination approaches
The Alzheimer’s drug development pipeline includes studies evaluating anti-amyloid monoclonal antibodies alongside other disease-modifying approaches, including combinations involving lecanemab and anti-tau therapies. This indicates increasing industry interest in targeting multiple pathological mechanisms rather than relying exclusively on amyloid removal.
Key Procurement Priorities and Buyer Evaluation Criteria
The procurement decision-making process in the Small Modular Reactor Market is being influenced by increasing demand for reliable low-carbon power generation, growing interest in nuclear energy for energy security, rising electricity consumption, and the need for flexible power generation solutions, driving buyers toward advanced SMR technologies that can support utilities, industrial facilities, remote locations, and emerging clean energy systems.
Buyers evaluate factors such as reactor safety, thermal efficiency, power output, fuel utilization, operating lifetime, scalability, construction requirements, maintenance needs, passive safety systems, and compliance with national and international nuclear safety standards when selecting small modular reactor technologies and suppliers.
The buyer considers reactor design maturity, modular construction capabilities, fuel technology, digital monitoring and control systems, grid integration, load-following capabilities, licensing readiness, supply chain reliability, and compatibility with existing nuclear and energy infrastructure while choosing technology partners for large-scale SMR deployments.
Procurement decisions are also shaped by sustainability and energy security objectives, with buyers evaluating suppliers based on greenhouse gas reduction potential, fuel efficiency, radioactive waste management, resource utilization, compatibility with renewable energy systems, and adherence to environmental and nuclear regulatory requirements.
Why Choose DataM?
Technological Innovations: Explores advancements in small modular reactor technologies, including pressurized water reactors, high-temperature gas-cooled reactors, molten salt reactors, fast reactors, advanced reactor designs, passive safety systems, modular construction techniques, and digital reactor monitoring technologies, enabling enhanced safety, operational flexibility, lower construction complexity, and scalable low-carbon power generation.
Product Performance & Market Positioning: Evaluates how different players deliver SMR solutions based on critical performance parameters such as reactor capacity, thermal efficiency, safety characteristics, fuel utilization, construction timelines, operating flexibility, lifecycle costs, modularity, and grid integration capabilities, highlighting how leading companies differentiate through advanced reactor designs, safety performance, scalability, and deployment readiness.
Real-World Evidence: Highlights the development, demonstration, licensing, and deployment of small modular reactor technologies across utilities, industrial facilities, remote communities, district heating applications, hydrogen production systems, and emerging clean energy projects, demonstrating benefits such as reliable baseload power, reduced carbon emissions, energy security, flexible generation, and integration with low-carbon energy systems.
Market Updates & Industry Changes: Tracks key developments such as SMR project announcements, reactor demonstrations, regulatory approvals, technology partnerships, government funding programs, nuclear energy policies, manufacturing capacity expansion, fuel technology advancements, and regional investments across North America, Europe, and Asia-Pacific, supporting the transition toward safer, flexible, and sustainable nuclear power infrastructure.
Competitive Strategies: Analyzes how leading companies expand through reactor technology innovation, strategic collaborations, joint ventures, acquisitions, government partnerships, licensing activities, manufacturing expansion, and integrated nuclear energy solutions to address increasing electricity demand, decarbonization targets, energy security requirements, and the growing need for flexible clean power generation.
Pricing & Market Access: Explains pricing variations based on reactor technology, power capacity, fuel type, project configuration, construction approach, deployment scale, regulatory requirements, infrastructure needs, and lifecycle costs, along with market access through utilities, nuclear technology providers, engineering and construction companies, government-backed programs, energy developers, and specialized nuclear infrastructure suppliers supporting global SMR deployment.
Market Entry & Expansion: Identifies growth opportunities driven by increasing nuclear energy investments, rising electricity demand, decarbonization initiatives, energy security concerns, replacement of aging power infrastructure, industrial electrification, and demand for reliable low-carbon power, while outlining strategies such as regional partnerships, technology licensing, regulatory engagement, manufacturing expansion, localized supply chains, and customized SMR solutions for emerging nuclear energy markets.
Target Audience
- Nuclear Power Plant Operators & Utilities
- Small Modular Reactor Technology Developers
- Nuclear Reactor Manufacturers & Technology Providers
- Nuclear Engineering, Procurement & Construction (EPC) Companies
- Nuclear Fuel Suppliers & Advanced Fuel Technology Companies
- Government Nuclear Energy Agencies & Regulatory Authorities
- Energy Infrastructure & Power Generation Companies
- Industrial Energy Consumers & Process Heat Providers
- Clean Energy Developers & Infrastructure Investors
- Nuclear Research Institutions & Technology Organizations
